Home › Activist investors › Harbert Discovery
Campaign activist. Positions and campaigns from Harbert Discovery’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| Enzo Biochem Inc | 9.9%5,175,913 shares | Schedule 13D/A, filed Jun 25, 2025 | Jun 25, 2025 | — | — | — | Seeks changes or engagement |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.
“On June 23, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Bethpage Parent, Inc., a Delaware corporation ("Bethpage"), and Bethpage Merger Sub, Inc., a New York corporation and a wholly owned subsidiary of Bethpage ("Merger Sub"). Pursuant to the terms of the Merger Agreement, Bethpage will acquire the Issuer in an all-equity…”
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Transact Technologies Inc | Stake reported below 5% | Sep 24, 2025 | Mar 31, 2022 | — | latest (2) | — |
| Enzo Biochem IncBoard seats | No campaign filings in the last 12 months | Feb 20, 2020 | Sep 17, 2019 | Proxy contest filed | latest (22) | — |
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| Transact Technologies Inc | 4.3% | Schedule 13D/A, filed Sep 24, 2025 | Reported below 5% in a 13D/A | Sep 24, 2025 |
| Streamline Health Solutions Inc. | 0.0% | Schedule 13D/A, filed Aug 14, 2025 | Exited | Aug 14, 2025 |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Transact Technologies Inc | Settlement | agreement with the company | Mar 31, 2022 | Mar 31, 2022 |
| Enzo Biochem Inc | No outcome in the filings read | — | Feb 20, 2020 | Sep 17, 2019 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 3 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Harbert Discovery’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.
| Holder | Form | Date | Stake |
|---|---|---|---|
| Radoff | Schedule 13D | Jun 25, 2025 | 0.0% |
| Battery Ventures XIV, L.P. | Schedule 13D | Jun 30, 2025 | 21.8% |